Replicel Life Sciences is a company that has developed a natural hair follicle cell replication and replacement technology for male and female pattern baldness that requires minimal surgery. This is huge because one of the main reasons why people don’t  have a hair transplant is because they don’t want to go through with the surgery which involves the removal of large portions of hair-bearing scalp from the back of the head which are then dissected into smaller hair clusters.  These clusters are then transplanted into balding areas on the scalp.  In contrast, Replicel’s procedure only requires the removal of approximately 10 - 20 healthy hair follicles from the back of the scalp where they remain strong. These follicles are dissected, isolating the dermal sheath cup cells and are replicated into the millions and prepared for injection into balding areas on the scalp.  The anticipated result, which is currently being testing in Phase I/IIa trials, is that the procedure will lead to new hair growth.  This is a huge medial breakthrough for the hair loss industry which is conservatively valued at over $3 billion a year (transplants + topical treatments).

REPCF Stock Quote: http://www.otcmarkets.com/stock/REPCF/quote

REPCF Stock Chart: Friday, April 27